Martin Richardet
Overview
Explore the profile of Martin Richardet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
933
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schenker M, Burotto M, Richardet M, Ciuleanu T, Goncalves A, Steeghs N, et al.
J Immunother Cancer
. 2024 Aug;
12(8).
PMID: 39107131
Background: Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies. This study evaluated the efficacy...
2.
Shore N, Gratzke C, Feyerabend S, Werbrouck P, Carles J, Vjaters E, et al.
Oncologist
. 2024 Feb;
29(7):581-588.
PMID: 38394384
Background: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) are usually asymptomatic and seek treatments that improve survival but have a low risk of adverse events. Darolutamide, a structurally distinct androgen...
3.
Choueiri T, Powles T, Burotto M, Escudier B, Bourlon M, Zurawski B, et al.
N Engl J Med
. 2021 Mar;
384(9):829-841.
PMID: 33657295
Background: The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known. Methods: In this...
4.
Motzer R, Escudier B, George S, Hammers H, Srinivas S, Tykodi S, et al.
Cancer
. 2020 Jul;
126(18):4156-4167.
PMID: 32673417
Background: CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long-term...
5.
Escudier B, Motzer R, Sharma P, Wagstaff J, Plimack E, Hammers H, et al.
Eur Urol
. 2017 Apr;
72(3):368-376.
PMID: 28410865
Background: Response patterns to nivolumab differ from those seen with other approved targeted therapies. Objective: To investigate the efficacy of nivolumab in previously treated patients with advanced renal cell carcinoma...
6.
Font A, Miguel Sanchez J, Taron M, Martinez-Balibrea E, Sanchez J, Luis Manzano J, et al.
Invest New Drugs
. 2003 Oct;
21(4):435-43.
PMID: 14586211
Purpose: Inherited variations in drug metabolizing enzymes may influence drug efficacy. This phase II study assesses the impact of second-line weekly irinotecan (CPT-11)/docetaxel in non-small cell lung cancer (NSCLC) patients,...
7.
Miguel Sanchez J, Balana C, Font A, Sanchez J, Luis Manzano J, Guillot M, et al.
Lung Cancer
. 2002 Nov;
38(3):309-15.
PMID: 12445754
Docetaxel and vinorelbine as single agents and in combination with cisplatin have shown significant activity in advanced non-small cell lung cancer (NSCLC). Significant neutropenia has been observed with the combination...